|Mr. Michael Bolinder||CEO & Director||1.13M||N/A||N/A|
|Mr. Gary G. Gemignani||Chief Financial Officer||N/A||N/A||1965|
|Dr. Gabriel Fox||Chief Medical Officer||N/A||N/A||N/A|
|Dr. Ian Walker||Head of Project Leadership||N/A||N/A||N/A|
|Anne-Marie Elsley||Company Sec.||N/A||N/A||N/A|
Acacia Pharma Group plc, a hospital pharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, other invasive procedures, or cancer chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an ultra-short-acting and reversible intravenous sedative benzodiazepine for the use in invasive medical procedures, such as bronchoscopies and colonoscopies; and APD403, an intravenous and oral amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. The company's products are primarily serves anesthesiologists and oncologists. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.
Acacia Pharma Group plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.